RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target

The global pandemic caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), named coronavirus disease 2019, has infected more than 8.9 million people worldwide. This calls for urgent effective therapeutic measures. RNA‐dependent RNA polymerase (RdRp) activity in viral transcription a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Medical Virology 2021-01, Vol.93 (1), p.300-310
Main Authors: Wang, Yanyan, Anirudhan, Varada, Du, Ruikun, Cui, Qinghua, Rong, Lijun
Format: Article
Language:English
Subjects:
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Coronaviridae
coronavirus
Coronaviruses
COVID-19
COVID-19 - drug therapy
COVID-19 - virology
DNA-directed RNA polymerase
drug target
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Inhibitors
Nucleoside analogs
Nucleosides - pharmacology
Nucleosides - therapeutic use
Pandemics
RdRp
Replication
Respiratory diseases
Ribonucleic acid
RNA
RNA polymerase
RNA-Dependent RNA Polymerase - antagonists & inhibitors
RNA-Dependent RNA Polymerase - genetics
RNA-Dependent RNA Polymerase - metabolism
SARS-CoV-2 - enzymology
SARS-CoV-2 - metabolism
SARS‐CoV‐2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Target recognition
Transcription
Viral diseases
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The global pandemic caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), named coronavirus disease 2019, has infected more than 8.9 million people worldwide. This calls for urgent effective therapeutic measures. RNA‐dependent RNA polymerase (RdRp) activity in viral transcription and replication has been recognized as an attractive target to design novel antiviral strategies. Although SARS‐CoV‐2 shares less genetic similarity with SARS‐CoV (~79%) and Middle East respiratory syndrome coronavirus (~50%), the respective RdRps of the three coronaviruses are highly conserved, suggesting that RdRp is a good broad‐spectrum antiviral target for coronaviruses. In this review, we discuss the antiviral potential of RdRp inhibitors (mainly nucleoside analogs) with an aim to provide a comprehensive account of drug discovery on SARS‐CoV‐2. Highlights RNA‐dependent RNA polymerase plays the vital role in SARS‐CoV‐2 viral replication. The relationship between structure and funcational of RNA polymerase. Evaluation and development of potential SARS‐CoV‐2 RdRp inhibitors.
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.26264